TRADING ON THE OTC - SYMBOL : PGUZ
OUR PRODUCTS : MEDICAL BACKGROUND & RESEARCH DATA : MANAGEMENT : INVESTORS/NEWS : LINKS : CONTACT US
CLICK IMAGE FOR LARGER VIEW

 

STAGES OF POTASSIUM TESTS

 

 

35 YEAR OLD MAN
DIAGNOSIS; HEALTHY

 

 

ORTHOSTATIC TEST

 

PATIENT WITH PACEMAKER VV1 AND TYPE 2 DIABETES

 

DECOMPESATED THYROTOXICOSIS

 

 

 

 

Home Page  |  

 

The HeartVue™ 6S System:

An Advanced ECG System Providing Physicians With Breakthrough Technology For Early, Non-Invasive Screening Of Heart Pathologies.

THE SYSTEM PROVIDES A 3D PORTRAIT OF THE HEART
IN JUST 60 SECONDS.

The Company's HeartVue™ 6S System will prove to be an invaluable screening tool for a wide range of diverse markets including cardiologists, general practitioners, physicians, intensive care units, hospitals, emergency rooms, clinics, fitness facilities, sports teams and other emergency medical facilities.

The HeartVue™ 6S System shows substantially greater sensitivity than a traditional ECG device with respect to ischemia and potentially superior diagnostic capabilities. With respect to screening for heart abnormalities, HeartPortrait'sT 6S System almost matched the sensitivity of a 12-lead ECG device read by an experienced cardiologist and was significantly superior on specificity. The Company's system has the potential for improving the speed and accuracy of diagnosing ischemic heart disease and other cardiac diseases that may not be identified by a traditional ECG device.

ADVANTAGES OF THE HeartVue™ 6S SYSTEM AS COMPARED TO A TRADITIONAL ECG SYSTEM:

  • The system's portability and speed of analysis add greatly to cutting the costs associated with the detection of ischemic heart disease.
  • Enables earlier detection of heart abnormalities.
  • Uses new information from ECG fluctuations that are usually ignored as "noise" by regular ECG devices.
  • The device allows a unique three dimensional color portrait of the heart's electrical field dynamics, allowing for rapid recognition and estimation of the heart's condition.
  • The HeartVue™ 6S System will depict a disease or stress level as an image instead of a line drawing electrocardiogram.
  • The Company's non-invasive screening system will provide more efficient clinical trials of new medications and treatment procedure results.
  • The system evaluates the stability of current heart conditions.
  • It improves disease-trend monitoring during medical treatment.
  • The system detects more cases of diseases and provides a better level of diagnosis with its improved sensitivity levels that can detect early warning signs that would normally be invisible with standard ECG devices. The device can detect small metabolic deviations preceding the dangerous ischemic damages of myocardium.
  • It differentiates arrhythmias and stresses.
 


Copyright © 2006, Pegasus Pharmaceuticals Inc.